By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a




Company News
TapImmune (TPIV) Release: Pharma Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients 1/10/2017 7:53:06 AM
TapImmune (TPIV): Year End 2016 Update 1/3/2017 7:24:52 AM
TapImmune (TPIV) Commences Trading On The Nasdaq Capital Market 11/9/2016 12:50:24 PM
TapImmune (TPIV) Approved For Listing On The Nasdaq Capital Market 11/3/2016 8:26:37 AM
TapImmune (TPIV) Announces Commercialization Pathway For Its HER2neu Vaccine 11/1/2016 8:19:57 AM
TapImmune (TPIV) President Dr. John Bonfiglio To Present At BioNetwork Partnering Summit On October 5, 2016 10/6/2016 9:42:13 AM
TapImmune (TPIV) Recognizes National Breast Cancer Awareness Month With Renewed Urgency To Develop Cancer Vaccines 10/4/2016 10:52:30 AM
TapImmune (TPIV) Announces Reverse Stock Split In Preparation For Proposed Uplisting To NASDAQ Capital Market 9/15/2016 10:04:49 AM
TapImmune (TPIV) Issues Update: Multiple Phase 2 Trials, Over $9 Million In New Funding & NASDAQ Uplisting Application 9/6/2016 8:28:12 AM
TapImmune (TPIV) Appoints Michael J. Loiacono As Chief Financial Officer 8/25/2016 10:00:55 AM